Health Equity/SDOH embedded in Payment Systems

Solomon J Lusinga, PhD (Director, US Value Evidence & Outcomes)
August 2023
### Enhancing Oncology Model

- Successor to Oncology Care Model (OCM)
- Oncology focused, voluntary payment model that pays for specific cancer types under a bundled payment for 6-month episodes
- Providers at risk for costs that exceed bundle
- Special focus on social determinants of health (SDOH) and health-related social needs (HRSN)

### ACO REACH

- Primary care/special-populations focused, voluntary payment model that provides capitated, prospective payment to the accountable care organization based on a population of patients
- 130+ accountable care organizations are participating, with an estimated 2.1 million covered lives
- Heavy focus on health equity
The Enhancing Oncology Model will require participants to collect SDOH and HRSN data, as well as ePROs.

- With this requirement, providers will gain insight on HRSN across their patient populations which will inform plans to implement efforts to mitigate those that impact patient access to care and outcomes.

- Practices will have to determine how they collect HRSN data.
For Pharma → address health equity in value demonstration for new drug products

- Address equity in registrational trial design and implementation
  - Use RWE on health equity to support clinical trial site recruitment and patient enrollment

- Incorporate equity objectives in evidence generation to support reimbursement decisions
  - Subgroup analyses in registrational trials?
  - Distributional cost-effectiveness
  - RWE in underrepresented groups in registrational trials?